Surrogate endpoints in assessment of new drugs in colorectal cancer.
Kelsen
D P
DP
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012074:Remission Induction; D015996:Survival Rate; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor